Dermatita atopica severa, approvazione e rimborsabilità tralokinumab per adolescenti tra 12 e 17 anni vantaggio per pazienti e medici’
(Adnkronos) - Il direttore medico di Leo Pharma Fabio Presutti, ‘avranno a diposizione da subito un nuovo farmaco che ha mostrato risultati importanti come efficacia e sicurezza e un nuovo device – una penna preriempita – che dimezzerà il numero delle somministrazioni aumentando l’aderenza alla terapia’
Category
🗞
NewsTranscript
00:00What are the benefits of the Traloquinumab?
00:04The approval and reimbursement of Traloquinumab in adolescent patients,
00:09i.e. at the age of 12-17, certainly represents an advantage,
00:15not only for patients as such, but also for the medical class,
00:19because they will immediately have a new drug
00:23that has shown significant results in terms of effectiveness and safety,
00:28and also an innovative device, a preemptive pen,
00:32which will halve the number of supplies,
00:35consequently increasing compliance with the drug itself.
00:38These are patients with severe atopic dermatitis,
00:41which is an extremely invalidating pathology in itself,
00:45but which especially in this age group of patients
00:49has implications not only dermatological, clinical,
00:53but also of psychosocial impact.
00:56Leofarma is a company that has more than 100 years of experience,
00:59and in the early years it has had an interest in all areas of therapy,
01:04i.e. diabetes, metabolism, etc.
01:06In recent years, the last 20 years,
01:09it has been a company committed solely to medical dermatology.
01:14For several years we have been, like Leofarma,
01:18a bit of a leader in topical therapy,
01:22with molecules considered a bit of a gold standard,
01:25essentially in psoriasis, infectious diseases, acne,
01:31and in the last five years we have entered the world of biologists.
01:35There are essentially two areas of development,
01:38at the moment it is psoriasis,
01:41with a development panel that goes from topical therapy to biological therapy,
01:48therefore for mild to severe forms,
01:51and then topical dermatology, which I referred to earlier.
01:55Here too we have drugs for mild forms, which are topical drugs,
02:02and biological drugs for more severe forms.
02:05Leofarma is committed daily to the research and development
02:10of new drugs in dermatology
02:14in areas that still have satisfactory needs,
02:18for example rare diseases.
02:20In dermatology there are a number of rare diseases,
02:24really significant, an important number,
02:27and so Leofarma is doing a daily scouting of new molecules,
02:32both of LEO development as such,
02:35or co-development with other companies,
02:38which can, as I said before,
02:40meet the satisfactory needs of dermatological patients.